[{"address1": "Hegenheimermattweg 167b", "city": "Allschwil", "zip": "4123", "country": "Switzerland", "phone": "41 61 606 11 11", "website": "https://www.basilea.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.", "fullTimeEmployees": 156, "companyOfficers": [{"maxAge": 1, "name": "Mr. David  Veitch", "age": 58, "title": "Chief Executive Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 1348319, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adesh  Kaul", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gerrit  Hauck Ph.D.", "age": 59, "title": "Chief Technology Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Laurenz  Kellenberger Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Engelhardt M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peer Nils Schroder", "title": "Head of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Damian  Heller", "age": 57, "title": "General Counsel & Corporate Secretary", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andreas  Kumin", "title": "Head of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ursula  Eberhardt", "age": 61, "title": "Head of Global Human Resources", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Jones", "age": 55, "title": "Head of Project Management & Preclinical Development", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 44.0, "open": 44.0, "dayLow": 44.45, "dayHigh": 44.45, "regularMarketPreviousClose": 44.0, "regularMarketOpen": 44.0, "regularMarketDayLow": 44.45, "regularMarketDayHigh": 44.45, "beta": 0.704, "volume": 100, "regularMarketVolume": 100, "averageVolume": 1, "marketCap": 648413376, "fiftyTwoWeekLow": 38.6, "fiftyTwoWeekHigh": 51.26, "priceToSalesTrailing12Months": 4.3511252, "fiftyDayAverage": 48.3674, "twoHundredDayAverage": 43.9541, "currency": "USD", "enterpriseValue": 670812352, "profitMargins": -0.00438, "floatShares": 11751663, "sharesOutstanding": 12121100, "heldPercentInsiders": 0.00056, "heldPercentInstitutions": 0.35649, "impliedSharesOutstanding": 12649500, "bookValue": 1.385, "priceToBook": 37.01083, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.349, "netIncomeToCommon": -652000, "trailingEps": -0.08, "enterpriseToRevenue": 4.501, "enterpriseToEbitda": -119.863, "52WeekChange": 0.02520001, "SandP52WeekChange": 0.24014747, "exchange": "OEM", "quoteType": "EQUITY", "symbol": "BPMUF", "underlyingSymbol": "BPMUF", "shortName": "BASILEA PHARMACEUTICA AG ALLSCH", "longName": "Basilea Pharmaceutica AG", "firstTradeDateEpochUtc": 1433856600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a2f90eec-a5fe-32af-a2a2-f7af3d6b3228", "messageBoardId": "finmb_1427461", "gmtOffSetMilliseconds": -14400000, "currentPrice": 51.26, "recommendationKey": "none", "totalCash": 62963000, "totalCashPerShare": 5.194, "ebitda": -5596500, "totalDebt": 112447000, "quickRatio": 2.962, "currentRatio": 4.103, "totalRevenue": 149022000, "debtToEquity": 669.886, "revenuePerShare": 12.372, "returnOnAssets": -0.020480001, "returnOnEquity": -0.04104, "freeCashflow": 13881375, "operatingCashflow": 10301000, "earningsGrowth": -0.332, "revenueGrowth": -0.101, "grossMargins": 0.16188, "ebitdaMargins": -0.037550002, "operatingMargins": 0.12473, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]